TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00611871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40mg placebo, followed 2 hrs after with 60mg placebo
Study: NCT00366639

Intervention type: OTHER
Intervention: Acute Decompensated Heart Failure
Description: Treatment \& outcomes during hospital admission for Acute DHF
Study: NCT02390518

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions.
Study: NCT01694771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: One dose
Study: NCT01821248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, S-1
Description: Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7
Study: NCT01694771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Marketed dose
Study: NCT00005596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study: NCT03757195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmentation
Description: combination product
Study: NCT06241222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Oral Tablet
Description: In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
Study: NCT01758601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)
Study: NCT01758601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)
Study: NCT00005596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: 2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: 2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: 60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: 60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
Study: NCT02326688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinematic analysis of trunk compensation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinematic analysis of trunk compensation
Study: NCT04065854

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
Study: NCT03768674

Intervention type: OTHER
Intervention: Assessment of diagnoses, functioning and health services
Description: Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services

Intervention type: OTHER
Intervention: Assessment of diagnoses, functioning and health services
Description: Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
Study: NCT02642679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opticell Ag
Description: Opticell Ag+ applied to STSG donor site
Study: NCT03203603

Intervention type: OTHER
Intervention: No active intervention
Description: This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.

Intervention type: OTHER
Intervention: No active intervention
Description: This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
Study: NCT02920853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Training (BT-CPR)
Description: Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
Study: NCT03332953

Intervention type: OTHER
Group type: OTHER
Intervention: E-cigarettes with varying concentrations of nicotine & flavor
Description: Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
Study: NCT01758601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood
Study: NCT01323491

Intervention type: DRUG
Intervention: Nicotine replacement therapy
Description: Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
Study: NCT02773992

Intervention type: BEHAVIORAL
Intervention: The IoT
Description: For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform.
Study: NCT02487745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent wage supplements
Description: Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Placement and Support (IPS) supported employment
Description: Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) supported employment
Description: Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
Study: NCT03203603

Intervention type: OTHER
Intervention: No active intervention
Description: This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
Study: NCT00170677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
Study: NCT00917020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: As-Needed during the 14 day Treatment Period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo Gas
Description: Placebo
Study: NCT02176525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01216085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose imatinib
Description: Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
Study: NCT03611335

Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)

Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)

Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)

Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)

Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)

Intervention type: BEHAVIORAL
Intervention: CATCH Interviews
Description: Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
Study: NCT03621995

Intervention type: OTHER
Intervention: Malondialdehyde and Catalase level measurement
Description: Malondialdehyde and Catalase level measurement by colorimetric method

Intervention type: OTHER
Intervention: Malondialdehyde and Catalase level measurement
Description: Malondialdehyde and Catalase level measurement by colorimetric method

Intervention type: OTHER
Intervention: Malondialdehyde and Catalase level measurement
Description: Malondialdehyde and Catalase level measurement by colorimetric method
Study: NCT01030042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-4
Description: Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
Study: NCT02920853

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback Training
Description: Participants will receive biofeedback training to reduce arousal and pain
Study: NCT03027479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samples
Description: Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
Study: NCT03894592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
Study: NCT03790007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In our study this local anesthetic agent will be applied for postoperative pain relief
Study: NCT02403388

Intervention type: OTHER
Intervention: PRisM
Description: A risk management program for each professional of care in multiprofessional primary care offices in France.
Study: NCT04163731

Intervention type: OTHER
Intervention: DASI questionnaire
Description: All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
Study: NCT01251146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
Study: NCT02810678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Latent Tuberculosis Infection program evaluation & diagnosis
Study: NCT00607932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brassica vegetable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indole-3-carbinol
Description: follow up at 2,4,6 months post baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indole-3-carbinol
Description: follow up at 2,4,6 months post baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: 2, 4, 6 months post baseline
Study: NCT02632253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MICE
Description: MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
Study: NCT00101439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Study: NCT01030042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan/Cetuximab
Description: CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.
Study: NCT02694029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Breathing Coordinator (ABC)
Description: The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Breathing Coordinator (ABC)
Description: The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisionRT
Description: A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VisionRT
Description: A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
Study: NCT04569539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the cricothyroid membrane
Study: NCT01516801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSA flyer
Description: A mailed low-literacy informational patient flyer about the PSA test
Study: NCT03721107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blautix
Description: Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blautix
Description: Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT06436521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Cognitive Behavioral Therapy
Description: Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Cognitive Behavioral Therapy
Description: Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
Study: NCT03491085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.